How to Inject Bicizumab Correctly to Ensure Best Results

Bimekizumab (Bimekizumab) is a biological agent for the systemic treatment of plaque psoriasis and related immune diseases. The standardization of its injection method is crucial to the therapeutic effect. In order to maximize the efficacy and reduce potential adverse reactions, patients and medical staff need to strictly follow the recommended regimen, especially in terms of dose regulation in the initial phase and long-term maintenance phase.

The standard injection regimen is usually subcutaneous injection, with a dose of 320mg each timeOne injection at week 0, week 4, week 8, week 12 and week 16. The intensive administration in this initial stage aims to quickly reach the steady-state concentration of the drug and quickly suppress the levels of IL-17A and IL-17F in the body, so that the therapeutic effect can be seen at an early stage. For patients with plaque psoriasis, following this initial course of treatment correctly can often significantly improve skin symptoms and achieve a PASI 75 to PASI 90 response between weeks 8 to 16.

After entering the maintenance treatment period, for patients whose weight is under 120 kg, it is recommended to inject 320mg every 8 weeks. This interval is more relaxed than many traditional biologics, helping to improve patients' medication compliance and quality of life. For patients weighing 120 kg or more, it is recommended to inject 320 mg every 4 weeks after the 16th week. This individualized dosage adjustment is mainly based on pharmacokinetic data to ensure that the drug maintains an effective concentration in the body to avoid a decrease in efficacy or recurrence of the condition.

Several key operations should be noted when injecting: First, the drug needs to be injected at the subcutaneous tissue layer. Common sites include the abdomen, front of the thigh, or outside of the upper arm. Avoid injecting into muscles or blood vessels. Secondly, check whether the liquid is clear and colorless before each injection, and avoid using turbid or precipitated liquids. Injection sites need to be changed regularly to reduce the risk of skin irritation or lipoatrophy.

Reference materials:https://www.drugs.com/bimekizumab.html